All Organoids articles
-
NewsUK’s first AI-robotic organoid lab opens in Liverpool
A £20 million high-security facility in Liverpool is set to accelerate drug and vaccine discovery by integrating artificial intelligence, robotics and human organoid technology within a Category 3 containment environment.
-
NewsPatient-derived tumour organoid biobank maps cancer gene dependencies
A biobank of 256 patient-derived tumour organoids, combined with genome-wide CRISPR–Cas9 screening, has produced a detailed map of cancer gene dependencies across five tumour types, revealing both shared vulnerabilities and mutation-specific targets with implications for precision oncology.
-
NewsEngineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
A preclinical study combining chemically modified suppressor tRNAs with inhaled lipid nanoparticles has restored functional CFTR protein production across bronchial epithelial cells, mouse models and patient-derived organoids, offering a potential new therapeutic strategy for nonsense mutation-driven cystic fibrosis.
-
ArticleSix assay requirements every researcher using NAMs should know
As NAMs become more widely used in drug discovery, assays must meet the demands of more complex models. Discover six requirements for reliable, reproducible and biologically meaningful data.
-
NewsStem cell-grown kidney organoids could help uncover new treatments for AKI
Researchers at Monash University have grown miniature human kidneys from stem cells that could give drug discovery teams a more human-relevant model for investigating acute kidney injury and identifying therapies that promote tissue recovery.
-
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
-
NewsNUS researchers identify molecular switch driving TNBC treatment resistance
Researchers at the National University of Singapore have identified DP103 as a potential molecular master switch sustaining tumour growth, cancer stem cells and treatment resistance in triple-negative breast cancer, with findings suggesting it could serve as a predictive biomarker for the investigational oral therapy RX-5902.
-
NewsPatient-specific brain tumour chip models vascular drug barriers
A microfluidic chip combining patient-derived glioblastoma cells with their tumour vascular environment could give drug developers a more realistic preclinical model for predicting treatment response – and may help explain why genetically similar patients respond differently to the same therapy.
-
NewsAGR2 and FOXM1 identified as prognostic and therapeutic targets in NF-PanNETs
A new study using single-cell RNA sequencing has identified AGR2 as a potential prognostic marker and FOXM1 as a druggable target in non-functional pancreatic neuroendocrine tumours, offering new tools to stratify patients and guide treatment strategies.
-
NewsHuman heart organoids with functioning valves model cardiac valve disorders
Researchers have engineered human heart organoids complete with functioning valves, creating a physiologically relevant platform to study valve disorders including mitral valve prolapse and valve calcification, and potentially accelerating the search for new treatments.
-
ArticleReducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials.
-
WebinarMeeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
-
NewsTumour organoids may expand access to targeted cancer drugs
Two studies from Weill Cornell Medicine demonstrate that patient-derived tumour organoids can accurately replicate cancers long-term and incorporate immune microenvironments, offering new potential for personalised treatment selection.
-
NewsCrown Bioscience joins C-Path coalition advancing regulatory NAMs acceptance
Crown Bioscience has joined the Critical Path Institute’s New Approach Methodologies Developer Coalition, bringing patient-derived model expertise and biomarker capabilities to efforts aimed at establishing regulatory qualification frameworks for human-relevant research tools.
-
NewsMIT engineers control blood vessel growth using mechanical stretching
Engineers at MIT have developed a technique to direct blood vessel growth using mechanical forces, offering a potential solution to one of tissue engineering’s most persistent obstacles: vascularisation.
-
NewsPancreas organoids reveal CFTR dysfunction as chronic pancreatitis drug target
Researchers at the Salk Institute have developed a patient-derived organoid platform that identifies distinct biological subtypes of chronic pancreatitis and highlights CFTR as a potential therapeutic target, raising prospects for more personalised treatments.
-
NewsMechanical forces key to realistic organ-on-chip laboratory models
A new review highlights how physical forces such as blood flow, breathing and tissue stiffness must be replicated alongside biochemical signals to produce physiologically accurate organoid and organ-on-chip models for disease research and drug testing.
-
NewsStem cell organoids repair heart microvessels in coronary artery disease models
Stanford University researchers have demonstrated that stem cell-derived vascular organoids can regenerate damaged microvessels in the heart, improving cardiac function in a porcine model of ischaemic heart disease and addressing a significant unmet need in coronary artery disease treatment.
-
ArticleOrgan chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
-
NewsSynthetic organiser cells enhance kidney organoid reproducibility and accuracy
Scientists at the University of Southern California have engineered synthetic organiser cells that produce localised Wnt signals to guide kidney organoid development, yielding more reproducible, physiologically accurate structures and revealing a previously unrecognised developmental axis in the human kidney.